Scotland backs Cabometyx combo for kidney cancer, amid stalled NICE reviewPatients in Scotland with newly-diagnosed advanced kidney cancer can now access a therapy combining Bristol-Myers Squibb’s immunotherapy Opdivo Share XScotland backs Cabometyx combo for kidney cancer, amid stalled NICE reviewhttps://pharmaphorum.com/news/scotland-backs-cabometyx-combo-for-kidney-cancer-amid-stalled-nice-review/
Ipsen hit by new palaver for rare disease drug palovaroteneJust as Ipsen’s $1 billion bet on rare bone disease drug palovarotene seemed to be nearing the finish Share XIpsen hit by new palaver for rare disease drug palovarotenehttps://pharmaphorum.com/news/ipsen-hit-by-new-palaver-for-rare-disease-drug-palovarotene/
Ipsen forges $1bn alliance with Exicure on neurodegenerative diseasesIpsen’s new chief executive David Loew pledged to ramp up spending on the company’s pipeline when he took Share XIpsen forges $1bn alliance with Exicure on neurodegenerative diseaseshttps://pharmaphorum.com/news/ipsen-forges-1bn-alliance-with-exicure-on-neurodegenerative-diseases/
Ipsen tries again in Parkinson’s disease with $363m IRLAB dealFrench drugmaker Ipsen has made another foray into the Parkinson’s disease category, licensing rights to an oral dopamine Share XIpsen tries again in Parkinson’s disease with $363m IRLAB dealhttps://pharmaphorum.com/news/ipsen-tries-again-in-parkinsons-disease-with-363m-irlab-deal/
Exelixis’ Cabometyx misses survival target in liver cancer trialExelixis has suffered a blow to its efforts to expand the use of Cabometyx into additional indications after Share XExelixis’ Cabometyx misses survival target in liver cancer trialhttps://pharmaphorum.com/news/exelixis-cabometyx-misses-survival-target-in-liver-cancer-trial/
Ipsen’s John Chaddock on making neurotoxins a priority for healthcare systemsInjected neurotoxins can be incredibly potent in treating spasticity from neurological diseases, but the field doesn’t always get Share XIpsen’s John Chaddock on making neurotoxins a priority for healthcare systemshttps://pharmaphorum.com/r-d/views-analysis-r-d/ipsens-john-chaddock-on-making-neurotoxins-a-priority-for-healthcare-systems/
Ipsen’s UK & Ireland MD on adapting business to COVID-19Since entering the pharmaceutical industry as a graduate trainee in the late 1990s, Asad Mohsin Ali’s career has Share XIpsen’s UK & Ireland MD on adapting business to COVID-19https://pharmaphorum.com/views-and-analysis/ipsens-uk-md-on-adapting-business-to-covid-19/
David Loew swaps Sanofi’s top vaccine job for CEO role at IpsenSanofi had no sooner announced the departure of David Loew, its head of vaccines, before he surfaced as Share XDavid Loew swaps Sanofi’s top vaccine job for CEO role at Ipsenhttps://pharmaphorum.com/news/david-loew-swaps-sanofis-top-vaccine-job-for-ceo-role-at-ipsen/
Engaging with customers in a digital worldAs part of our series on customer experience in pharma, in partnership with Indegene, Ipsen’s Paul Murasko explains Share XEngaging with customers in a digital worldhttps://pharmaphorum.com/views-analysis-digital/engaging-with-customers-in-a-digital-world/
